As an integrin alpha-4 antagonist, AXR-159 is a first-in-class therapeutic with steroid-like efficacy in preclinical models targeting a novel mechanism in the eye for the chronic treatment of DED. AXR-159 has been tested extensively in preclinical models of efficacy and safety and has successfully completed a Phase 2 clinical proof-of-concept study.
AXR-159